Accordingly, we propose that upregulation of tumor-suppressive KRT7-AS in cancer cells is a sensible strategy for developing novel therapeutics against lung and breast cancers, and other KRT7-AS deficient malignant tumors as well. This evidence concerns the gene KRT7 and cancer.